To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

NCT05356741 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

645

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced or Metastatic HER2-Expressing Cancers

Interventions

DRUG: VIR-5818
DRUG: pembrolizumab

Sponsor

Vir Biotechnology, Inc.

Collaborators

[object Object]